In silico development of a multi-epitope-based vaccine against Burkholderia cepacia complex using reverse vaccinology
BackgroundMultidrug-resistant Burkholderia cenocepacia and Burkholderia multivorans have emerged as significant pathogens, particularly in patients with cystic fibrosis (CF) and chronic granulomatous disease (CGD).ObjectiveGiven the absence of approved vaccines, this study aimed to identify potentia...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Virology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fviro.2025.1520109/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589829846597632 |
|---|---|
| author | Donya Ghorbani Donya Ghorbani Masoumeh Beig Masoumeh Beig Narjes Noori Goodarzi Mohammad Sholeh Mohammad Sholeh Behzad Shahbazi Behzad Shahbazi Yaser Moghaddam Farzad Badmasti |
| author_facet | Donya Ghorbani Donya Ghorbani Masoumeh Beig Masoumeh Beig Narjes Noori Goodarzi Mohammad Sholeh Mohammad Sholeh Behzad Shahbazi Behzad Shahbazi Yaser Moghaddam Farzad Badmasti |
| author_sort | Donya Ghorbani |
| collection | DOAJ |
| description | BackgroundMultidrug-resistant Burkholderia cenocepacia and Burkholderia multivorans have emerged as significant pathogens, particularly in patients with cystic fibrosis (CF) and chronic granulomatous disease (CGD).ObjectiveGiven the absence of approved vaccines, this study aimed to identify potential vaccine candidates against these pathogens.MethodsThe complete genomes of B. cenocepacia and B. multivorans were retrieved from the GenBank. Surface-exposed proteins that were antigenic, non-allergenic, and non-homologous to human proteins were selected for further analysis. The conserved domains of the selected proteins were analyzed, and their presence was examined across 68 genomes. Subsequently, linear and conformational B-cell epitopes and human MHC II binding sites were identified. Highly conserved and immunogenic B-cell epitopes from outer membrane proteins (OMPs) were incorporated into a multi-epitope vaccine (MEV). Molecular docking analysis was performed to assess the interaction of the selected proteins. Finally, molecular dynamics (MD) simulations were conducted using GROMACS 2019 to evaluate the feasibility and dynamics of the interactions between the chimeric MEV and Toll-like receptor complexes, TLR2 and TLR4.ResultsOf 16,723 proteins identified in B. multivorans and B. cenocepacia strains, nine proteins (six OMPs and three extracellular) were selected as ideal candidates based on established criteria. These proteins had a molecular weight of 110 kDa and were present in ≥ 75% of the dataset of B. multivorans and B. cenocepacia genomes. In addition, molecular docking and MD indicated stable and feasible interactions between MEV and TLRs. The MEV-TLR4 system demonstrates the greatest stability and tightly bound interaction, with minimal fluctuations and high structural integrity. In contrast, the MEV-only system exhibits significant flexibility and dynamic behavior as a free ligand, while the MEV-TLR2 system balances stability and flexibility, showing a dynamic but stable interaction.ConclusionNine potential immunogenic proteins were identified as viable targets for vaccine development. An optimized MEV was explicitly designed for B. multivorans and B. cenocepacia. The novel MEV platform exhibited high binding affinity to immune receptors and favorable molecular docking characteristics. Although these findings are encouraging, additional in vitro and in vivo testing is necessary to validate the vaccine’s effects. |
| format | Article |
| id | doaj-art-386a086e11944ca89ba001c64b13000b |
| institution | Kabale University |
| issn | 2673-818X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Virology |
| spelling | doaj-art-386a086e11944ca89ba001c64b13000b2025-01-24T07:13:52ZengFrontiers Media S.A.Frontiers in Virology2673-818X2025-01-01510.3389/fviro.2025.15201091520109In silico development of a multi-epitope-based vaccine against Burkholderia cepacia complex using reverse vaccinologyDonya Ghorbani0Donya Ghorbani1Masoumeh Beig2Masoumeh Beig3Narjes Noori Goodarzi4Mohammad Sholeh5Mohammad Sholeh6Behzad Shahbazi7Behzad Shahbazi8Yaser Moghaddam9Farzad Badmasti10Department of Bacteriology, Pasteur Institute of Iran, Tehran, IranMedical Genomics Research Centre, Tehran Medical Sciences, Islamic Azad University, Tehran, IranDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, IranStudent Research Committee, Pasteur Institute of Iran, Tehran, IranDepartment of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, IranDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, IranStudent Research Committee, Pasteur Institute of Iran, Tehran, IranSchool of Pharmacy, Semnan University of Medical Sciences, Semnan, IranNervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, IranDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, IranDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, IranBackgroundMultidrug-resistant Burkholderia cenocepacia and Burkholderia multivorans have emerged as significant pathogens, particularly in patients with cystic fibrosis (CF) and chronic granulomatous disease (CGD).ObjectiveGiven the absence of approved vaccines, this study aimed to identify potential vaccine candidates against these pathogens.MethodsThe complete genomes of B. cenocepacia and B. multivorans were retrieved from the GenBank. Surface-exposed proteins that were antigenic, non-allergenic, and non-homologous to human proteins were selected for further analysis. The conserved domains of the selected proteins were analyzed, and their presence was examined across 68 genomes. Subsequently, linear and conformational B-cell epitopes and human MHC II binding sites were identified. Highly conserved and immunogenic B-cell epitopes from outer membrane proteins (OMPs) were incorporated into a multi-epitope vaccine (MEV). Molecular docking analysis was performed to assess the interaction of the selected proteins. Finally, molecular dynamics (MD) simulations were conducted using GROMACS 2019 to evaluate the feasibility and dynamics of the interactions between the chimeric MEV and Toll-like receptor complexes, TLR2 and TLR4.ResultsOf 16,723 proteins identified in B. multivorans and B. cenocepacia strains, nine proteins (six OMPs and three extracellular) were selected as ideal candidates based on established criteria. These proteins had a molecular weight of 110 kDa and were present in ≥ 75% of the dataset of B. multivorans and B. cenocepacia genomes. In addition, molecular docking and MD indicated stable and feasible interactions between MEV and TLRs. The MEV-TLR4 system demonstrates the greatest stability and tightly bound interaction, with minimal fluctuations and high structural integrity. In contrast, the MEV-only system exhibits significant flexibility and dynamic behavior as a free ligand, while the MEV-TLR2 system balances stability and flexibility, showing a dynamic but stable interaction.ConclusionNine potential immunogenic proteins were identified as viable targets for vaccine development. An optimized MEV was explicitly designed for B. multivorans and B. cenocepacia. The novel MEV platform exhibited high binding affinity to immune receptors and favorable molecular docking characteristics. Although these findings are encouraging, additional in vitro and in vivo testing is necessary to validate the vaccine’s effects.https://www.frontiersin.org/articles/10.3389/fviro.2025.1520109/fullBccreverse vaccinologyin silicomulti-epitope vaccinetoll-like receptors |
| spellingShingle | Donya Ghorbani Donya Ghorbani Masoumeh Beig Masoumeh Beig Narjes Noori Goodarzi Mohammad Sholeh Mohammad Sholeh Behzad Shahbazi Behzad Shahbazi Yaser Moghaddam Farzad Badmasti In silico development of a multi-epitope-based vaccine against Burkholderia cepacia complex using reverse vaccinology Frontiers in Virology Bcc reverse vaccinology in silico multi-epitope vaccine toll-like receptors |
| title | In silico development of a multi-epitope-based vaccine against Burkholderia cepacia complex using reverse vaccinology |
| title_full | In silico development of a multi-epitope-based vaccine against Burkholderia cepacia complex using reverse vaccinology |
| title_fullStr | In silico development of a multi-epitope-based vaccine against Burkholderia cepacia complex using reverse vaccinology |
| title_full_unstemmed | In silico development of a multi-epitope-based vaccine against Burkholderia cepacia complex using reverse vaccinology |
| title_short | In silico development of a multi-epitope-based vaccine against Burkholderia cepacia complex using reverse vaccinology |
| title_sort | in silico development of a multi epitope based vaccine against burkholderia cepacia complex using reverse vaccinology |
| topic | Bcc reverse vaccinology in silico multi-epitope vaccine toll-like receptors |
| url | https://www.frontiersin.org/articles/10.3389/fviro.2025.1520109/full |
| work_keys_str_mv | AT donyaghorbani insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT donyaghorbani insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT masoumehbeig insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT masoumehbeig insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT narjesnoorigoodarzi insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT mohammadsholeh insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT mohammadsholeh insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT behzadshahbazi insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT behzadshahbazi insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT yasermoghaddam insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology AT farzadbadmasti insilicodevelopmentofamultiepitopebasedvaccineagainstburkholderiacepaciacomplexusingreversevaccinology |